Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence
References (27)
- et al.
Gout
Lancet
(2010) - et al.
Prevalence of contraindications and prescription of pharmacologic therapies for gout
Am J Med
(2011) Developments in the scientific and clinical understanding of gout
Arthritis Res Ther
(2008)Gout
N Engl J Med
(2011)- et al.
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
Ann Rheum Dis
(2012) - et al.
Quality of life and disability in patients with treatment-failure gout
J Rheumatol
(2009) - et al.
Perceptions of disease and health-related quality of life among patients with gout
Rheumatology
(2009) - et al.
2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
Arthritis Care Res
(2012) - et al.
Canakimuab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study
Arthritis Rheum
(2010) Difficult-to-treat gouty arthritis
A disease warranting better management. Drugs
(2011)
Independent impact of gout on mortality and risk for coronary heart disease
Circulation
Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey
Arthritis Rheum
Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile
Rheumatology
Cited by (11)
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout
2021, The Lancet RheumatologyCitation Excerpt :As data on patients with gout are scarce, one can only speculate as to whether the typically short treatment duration has any unfavourable cardiovascular effects. In 2013, the anti-IL-1β antibody canakinumab was approved by the FDA and the European Medicines Agency for gout inflammation refractory to conventional anti-inflammatory treatment.95 A 2019 trial of the IL-1 receptor antagonist, anakinra, showed efficacy in controlling inflammation during gout flare without cardiovascular safety issues.96
New perspectives on traumatic bone infections
2020, Chinese Journal of Traumatology - English EditionCitation Excerpt :IL-1 antagonists directly inhibit the differentiation and functional activation of osteoclasts while reducing the inflammatory response.52 IL-1 inhibitors are mainly used in diseases where IL-1β is the main causative factor, such as gout.53 Another small molecule inhibitor of NLRP3 inflammatory corpuscle has also been used in many mouse disease models, demonstrating that inflammatory corpuscles are also an effective target for such diseases, but there are no clinical reports of such drugs.54
Benefit-risk of corticosteroids in acute gout patients: An updated meta-analysis and economic evaluation
2017, SteroidsCitation Excerpt :Second, corticosteroids may have preferable analgesic efficacy over traditional NSAIDs (e.g. indomethacin or diclofenac sodium), but not over COX-2 selective inhibitors (e.g. celecoxib) or canakinumab. One study recommends canakinumab as a treatment option in a target population with frequent gouty arthritis attacks who are unable to use NSAIDs and colchicine and could not frequently use corticosteroids [30]. Third, we set point-in-time at day 5 as the final outcome, aiming to avoid the impact of spontaneous remission since the self-limitation of acute gout could interfere with the efficacy analysis.
Septic Arthritis Complicating a Gout Flare: Report of Two Cases and Review of the Literature
2022, Mediterranean Journal of RheumatologyGasdermin D deficiency attenuates arthritis induced by traumatic injury but not autoantibody-assembled immune complexes
2021, Arthritis Research and Therapy30 Years of Biotherapeutics Development-What Have We Learned?
2020, Annual Review of Immunology